Please check your internet connection and try again.
## Overview
Daptomycin is a cyclic lipopeptide antibiotic active against aerobic Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). It exerts its bactericidal effect by causing rapid depolarization of the bacterial membrane potential, leading to inhibition of DNA, RNA, and protein synthesis.
## Primary Indications
* **Complicated skin and skin structure infections (cSSSI)**: Caused by susceptible Gram-positive bacteria.
* **_Staphylococcus aureus_ bloodstream infections (bacteremia)**: Including right-sided infective endocarditis, caused by susceptible *S. aureus* isolates.
## Adult Dosing
* **cSSSI**: 4 mg/kg intravenously once every 24 hours for 7 to 14 days.
* **_S. aureus_ bacteremia**: 6 mg/kg intravenously once every 24 hours for at least 7 days, or longer based on clinical response and source of bacteremia.
* **_S. aureus_ bacteremia with endocarditis or osteomyelitis**: 8 mg/kg intravenously once every 24 hours.
## Pediatric Dosing
Dosing in pediatric patients is not well established and should be guided by expert consultation and institutional protocols. Limited data exists for dosages ranging from 4 mg/kg to 10 mg/kg once every 24 hours for various Gram-positive infections.
## Dose Adjustments
* **Renal Impairment**:
* CrCl < 30 mL/min:Administer every 48 hours (e.g., 4 mg/kg every 48 hours for cSSSI; 6 mg/kg every 48 hours for bacteremia). Further dose reduction may be necessary in patients on hemodialysis.
## Contraindications
* Hypersensitivity to daptomycin or any component of the formulation.
## Adverse Effects
* **Most Common**: Headache, dizziness, rash, nausea, vomiting, diarrhea, constipation, abdominal pain, injection site reactions.
* **Serious**:
* **Myopathy and Rhabdomyolysis**: Characterized by muscle pain and weakness, with elevated creatine phosphokinase (CPK) levels.
* **Eosinophilic pneumonia**: Cough, dyspnea, fever, hypoxemia, pulmonary infiltrates.
* **Peripheral neuropathy**: Numbness, tingling, pain in extremities.
* **Hypersensitivity reactions**.
## Key Drug Interactions
* **Warfarin**: Daptomycin may increase the INR of patients on warfarin. Monitor INR closely and adjust warfarin dose as needed.
* **HMG-CoA reductase inhibitors (statins)**: Coadministration with statins may increase the risk of myopathy. Discontinue statin therapy during daptomycin treatment if possible.
## Monitoring
* **Creatine phosphokinase (CPK)**: Monitor baseline CPK and weekly thereafter, or more frequently in patients experiencing muscle pain or weakness. If CPK > 2 times the upper limit of normal (ULN) without myopathy, consider reducing dose or discontinuing therapy. If CPK > 5 times ULN with myopathy, discontinue daptomycin.
* **Renal function**: Monitor serum creatinine and BUN.
* **Liver function tests**: Monitor baseline and periodically.
* **INR**: In patients receiving warfarin.
* **Signs and symptoms of eosinophilic pneumonia and peripheral neuropathy**.
## Clinical Pearls
* Daptomycin is **not effective** for meningitis due to poor penetration into cerebrospinal fluid.
* Reconstituted solution should **not be inhaled**.
* Daptomycin is inactivated in the lung and is **not approved** for the treatment of pneumonia.
* Optimal duration of therapy for bacteremia needs to be individualized based on clinical response and source of infection.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature before making clinical decisions.*
